WASHINGTON, D.C.—On Sept. 14, the ACR praised the House of Representatives for overwhelmingly passing bipartisan legislation intended to make it easier for Medicare Advantage beneficiaries to access the timely care they need. The Improving Seniors’ Timely Access to Care Act (H.R. 3173) passed the House on a voice vote. If enacted, the bill will create…
ATLANTA—The ACR released a summary of its updated guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in September. Many patients take glucocorticoids for a variety of inflammatory conditions, and anyone who is taking glucocorticoid medications and has other risk factors for osteoporosis increases their risk of developing glucocorticoid-induced osteoporosis. New osteoporosis medications and new…
On Sept. 13, the ACR and Kevin D. Deane, MD, PhD, presented a proposal to create a new clinical code to recognize a condition in which an individual may exhibit rheumatoid arthritis-related autoantibodies without clinical presentation.
Patient stories are a powerful way to highlight ways that healthcare policies affect the everyday lives of people with rheumatic diseases.
ACR Convergence 2022 will offer several opportunities to learn to leverage your expertise to support the rheumatology community, keep practices solvent and improve care of patients with rheumatic diseases. Look for sessions that explore why and how to pursue effective rheumatology advocacy and how to turn challenges into actionable results.
Applications are now being accepted for the ACR Fellows-in-Training Subcommittee, which works on educational programming and projects. Learn how you can get involved.
Ongoing ACR advocacy efforts are working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologic therapies.
Many members of Congress return to their home states and districts in August, making it a great time to engage them in local conversations about healthcare policies and how they affect rheumatology practices and patients.
If enacted as is, the proposed CY 2023 Medicare Physician Fee Schedule and Quality Payment Program would make significant cuts to reimbursement for evaluation and management services, creating financial instability for providers. On a positive note, it would extend some telehealth flexibilities 151 days beyond the official end of the public health emergency.
Cigna will not move forward with changes to their reimbursement policy for evaluation and management (E/M) codes submitted with modifier 25 as originally scheduled.